Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company Deals

WuXi XDC Expands MOU with LigaChem to Advance Next-Gen ADC Development

Fineline Cube Feb 26, 2025

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Deals

Kexing Biopharm and Bio-Sincerity Pharmaceutical Form Strategic Alliance

Fineline Cube Feb 26, 2025

China-based Kexing Biopharm Co., Ltd. (SHA: 688136) and Hangzhou Bio-Sincerity Pharmaceutical Technology Co., Ltd. (SHE:...

Company Deals

Harbour BioMed Licenses HAT001/HBM9013 to Global Partner for CRH-Targeted Therapy

Fineline Cube Feb 26, 2025

China-based Harbour BioMed (HKG: 2142) announced a strategic collaboration and licensing agreement with an undisclosed...

Company Deals Hospital

Basecare and Rhea Labs Form Five-Year Alliance to Expand IVF Markets Globally

Fineline Cube Feb 26, 2025

China-based IVF specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) has entered into a five-year...

Company Deals

Takeda Partners with BridGene to Develop Immunology and Neurology Drug Candidates

Fineline Cube Feb 26, 2025

Japan-based Takeda Pharmaceutical Company (NYSE: TAK, TYO: 4502) announced a partnership with US-based BridGene Biosciences,...

Company Deals

Hansoh Pharmaceutical’s HS-10561 Receives NMPA Clearance for Chronic Spontaneous Urticaria

Fineline Cube Feb 26, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received clinical trial...

Company Medical Device

J&J MedTech Launches Locally Produced HARMONIC 7s Scalpel in China

Fineline Cube Feb 26, 2025

Johnson & Johnson MedTech, a US-based healthcare giant, announced the official launch of its HARMONIC...

Company Deals

Thermo Fisher to Acquire Solventum’s Purification Business for USD 4.1B

Fineline Cube Feb 26, 2025

Thermo Fisher Scientific (NYSE: TMO) has agreed to acquire Solventum’s (NYSE: SOLV) Purification & Filtration...

Company Drug

J&J’s Tremfya Wins NMPA Approval for Crohn’s Disease Treatment

Fineline Cube Feb 26, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that its Tremfya (guselkumab) has received marketing approval...

Company Drug

Sanofi’s Sarclisa Wins New Japan Approval for Multiple Myeloma Combination Therapy

Fineline Cube Feb 26, 2025

Sanofi (EPA: SAN, NASDAQ: SNY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW)...

Company Drug

YolTech Therapeutics’ YOLT-203 Shows Promise in Primary Hyperoxaluria Type 1 Trial

Fineline Cube Feb 26, 2025

YolTech Therapeutics, a Shanghai-based startup specializing in lipid nanoparticle delivery and gene editing, announced positive...

Company Deals

HQ Pharma and Shanghai Pharmaceuticals Expand Collaboration for Global Market Access

Fineline Cube Feb 26, 2025

China’s HQ Pharma (Shanghai) Co., Ltd has entered into a new collaboration agreement with Shanghai...

Company Deals

Green Valley and Vazyme Team Up on Alzheimer’s Disease Initiatives

Fineline Cube Feb 26, 2025

China-based Green Valley (Shanghai) Pharmaceuticals Co., Ltd. and Vazyme Biotech Co., Ltd (SHA: 688105) have...

Company Drug

Merck’s Keytruda sBLA for LA-HNSCC Accepted by FDA for Review

Fineline Cube Feb 26, 2025

Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced that the US Food and Drug...

Company Deals

CARsgen Therapeutics and Zhuhai SB Xinchuang Invest in UCARsgen for Allogeneic CAR-T Therapies

Fineline Cube Feb 26, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has entered into an agreement with an investment...

Company Drug

Eli Lilly Launches New Zepbound Doses with Lower Prices for Self-Pay Patients

Fineline Cube Feb 26, 2025

Eli Lilly & Co. (NYSE: LLY) announced the launch of 7.5 mg and 10 mg...

Company Drug

Suzhou Ribo Life Science’s RBD2080 siRNA Drug Receives Australian Clinical Trial Approval

Fineline Cube Feb 26, 2025

China-based Suzhou Ribo Life Science Co., Ltd announced that its siRNA drug RBD2080 has received...

Company

MicuRx Pharmaceuticals Sues Medpace Over Breach of Contract in Phase III Study

Fineline Cube Feb 26, 2025

Sino-US biotech firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has filed a lawsuit against US-based Medpace,...

Company Deals

Eli Lilly Acquires Organovo’s FXR Program for Inflammatory Bowel Disease

Fineline Cube Feb 26, 2025

US-based Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical-stage biotech focused on inflammatory bowel disease (IBD),...

Company Medical Device

Acotec Scientific’s Vericor Catheter Wins NMPA Approval for Peripheral Vascular Surgery

Fineline Cube Feb 25, 2025

China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that its peripheral disposable support catheter Vericor...

Posts pagination

1 … 143 144 145 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.